Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Sekisui Diagnostics

Download Mobile App




Immunoassay Module Integrated on Platform with Clinical Chemistry

By LabMedica International staff writers
Posted on 29 Jul 2010
A new immunoassay module can be integrated with clinical chemistry testing on a single platform.

The latest addition to the cobas 8000 platform suitable for large volume labs is the cobas e 602 module. More...
It runs more than 80 different immunoassays--from high medical value tests for cardiac and infectious diseases to bone markers, rheumatoid arthritis, tumor markers, and tests for maternal care--with a throughput of 170 tests per hour.

The cobas 8000 modular analyzer series offer 19 different configurations and has many new design and process elements such as the module sample buffer in each module, independent transport and return lines, switch gates, and many more features optimizing sample routing to achieve maximum efficiency and productivity.

In addition, the new cobas e 602 module uses the same operator interface, detection technologies and reagents as other cobas instruments, enabling standardization of results between different analyzers.

The cobas 8000 modular analyzer series is the newest member of Roche's (Basel, Switzerland) cobas modular platform family. It is designed to meet the needs of high volume laboratories with about 3 to 15 million tests per year to deliver high quality results quickly and efficiently from a single patient sample. The cobas 8000 compliments the cobas 6000 modular analyzer for medium-sized laboratories and the cobas 4000 systems for small workloads.

Roche offers seven additional configurations to the cobas 8000 modular analyzer series by combining the previously launched clinical chemistry modules with the immunoassay module for serum work area testing.

The new cobas e 602-immunoassay module is available in Europe as well as in all countries recognizing CE marking in the Latin America and Asia-Pacific regions.

With the launch of the high volume immunochemistry module, customers can consolidate clinical chemistry and immunochemistry testing in different ways into one single configuration. The cobas 8000 modular analyzer series offers 19 different configurations and includes many design and process elements such as the Module Sample Buffer in each module, independent transport and return lines, switch gates, and other features optimizing sample routing to achieve maximum efficiency and productivity.

Roche is a leader in research-focused healthcare with combined strengths in diagnostics and pharmaceutics. The company is an important provider of in vitro diagnostics (IVD), tissue-based cancer diagnostics, and diabetes management.

Related Links:

Roche's



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Nucleic Acid Purification Instrument
QIAsymphony Connect
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Study design and workflow (Parankusham H, Vanderlip C, Birkenbihl C, et al. A two-stage plasma biomarker algorithm reduces amyloid PET use and the p-Tau217 gray zone. Annals of Clinical and Translational Neurology. Published online October 19, 2026. doi:10.1002/acn3.70560)

Two-Step Blood Testing Approach Reduces Uncertainty in Amyloid Assessment

Blood-based biomarkers offer a more accessible, less expensive way to detect Alzheimer’s-related brain changes than traditional methods such as amyloid-beta positron emission tomography (Aβ-PET).... Read more

Molecular Diagnostics

view channel
Image: Tumor DNA is extracted from a pathology sample, and normal DNA is extracted from the buffy coat. Both samples undergo WGS to generate the patient-specific mutational signature. At each follow-up, ctDNA extracted from plasma undergoes WGS and is analyzed using a patient-derived signature and an artificial intelligence (AI) pattern recognition algorithm. FFPE: formalin fixed, paraffin embedded. (Snuderl M, Smadbeck J, Wilkins R, et al. The Journal of Molecular Diagnostics, 2026. DOI: 10.1016/j.jmoldx.2026.07.003)

Liquid Biopsy Detects Lung Cancer Recurrence Signals Months Before Imaging

Non-small cell lung cancer (NSCLC) is the most common type of lung cancer and remains a major cause of cancer-related death. Early-stage tumors are often treated surgically, but recurrence can still occur... Read more

Pathology

view channel
Image: HETA Quality Control identifies slide quality issues before analysis, while HETA Tumor Detect annotates tumor regions and flags slides likely to contain tumor during scanning. (Photo courtesy of Aignostics)

AI Pathology Platform Targets Workflow Delays and Molecular Test Failures

Pathology laboratories often rely on visual review of tissue slides to assess quality, identify tumors, count mitoses, and estimate tumor content. These tasks can be time-consuming and vary between readers,... Read more

Technology

view channel
Image: Signals LabGistics uses AI to turn natural-language instructions and SOPs into coordinated scientific workflows, helping connect teams, systems, and processes. (Photo courtesy of Revvity)

New AI-Powered System Aims to Streamline Laboratory and Manufacturing Workflows

Scientific laboratories supporting drug development, biotechnology, and materials research increasingly rely on coordinated digital workflows to move data, samples, and activities across teams.... Read more

Industry

view channel
Image: The acquisition of Reveal Genomics would expand Hologic’s oncology diagnostics portfolio to support treatment decisions for more women with breast cancer.

Hologic to Broaden Breast Cancer Testing Portfolio Through Reveal Genomics Acquisition

Hologic (Marlborough, MA, USA) has signed a definitive agreement to acquire Reveal Genomics (Barcelona, Spain), a precision oncology company developing genomic diagnostic tests to help personalize cancer treatment.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.